| |
Download our guide to learn how to navigate the complex European landscape and gain insights on how late-stage customization could make your European distribution simpler and more efficient. Download now.
|
|
Today’s Big NewsOct 16, 2023 |
| By Nick Paul Taylor Omeros has stopped a phase 3 trial of narsoplimab in kidney disease patients after an interim analysis found it was destined to fail, adding another plot line to its epic, ongoing attempt to get the candidate to market. |
|
|
|
By Annalee Armstrong Howard Fillit, M.D., remembers a time when doctors didn’t have a name for the condition that robbed elderly patients of their memory. He’s a geriatrician and neuroscientist, but also the co-founder and chief science officer for the Alzheimer’s Drug Discovery Foundation. |
By Nick Paul Taylor Novo Nordisk is putting its soaring sales to work, agreeing to pay up to $1.3 billion for KBP Biosciences’ phase 3 challenger to Bayer’s chronic kidney disease drug Kerendia. |
Sponsored by Tanvex CDMO Reacting to the growth of biotherapeutics, Tanvex BioPharma USA, Inc., is set to launch Tanvex CDMO, a full-service CDMO specializing in mammalian- and microbial-derived biologics and biosimilars. |
|
Best-in-class thermostability and excellent inhibitor tolerance deliver compatibility across a range of clinically relevant samples and superior results in pathogen detection assays. Lyophilization-friendly formats available. Learn more.
|
|
By Annalee Armstrong In September 2019, a tiny company named SAB Biotherapeutics signed a little contract with the U.S. Department of Defense that included the development of an antibody treatment into phase 1 for “an unknown threat.” The rest, as they say, is history. |
By James Waldron Five months after its acquisition of Atea Pharmaceuticals fell through, Concentra Biosciences has set its sights on another struggling biotech: Rain Oncology. |
By James Waldron The acquisition of Synaffix continues to look like a good move by Lonza, with a cancer-focused biotech signing a $740 million biobucks deal to access its antibody-drug conjugate capabilities. |
By Helen Floersh Probiotics could be the key to making universal chimeric antigen receptor T cell therapies work for solid tumors, new research has suggested. |
By Kevin Dunleavy Pfizer has slashed its 2023 revenue projection by $9 billion because of declining demand for COVID products. The company now expects sales to reach between $58 billion and $61 billion, down from a prior range of $67 billion to $70 billion. Pfizer chalked up most of the decline to a $7 billion decrease in its projection for sales of oral antiviral Paxlovid. The company has also cut its forecast for sales of COVID vaccine Comirnaty by $2 billion. |
By Angus Liu AbbVie already shared last month that its Skyrizi had trounced Johnson & Johnson’s rival biologic drug Stelara in Crohn’s disease. Now, detailed trial results show just how decisive Skyrizi’s win is. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Zoey Becker Lonza's expanded collaboration with a "major biopharmaceutical partner" came right after a separate similar announcement. The latest project will allow Lonza to add 115 jobs in Switzerland. |
Fierce podcastsDon’t miss an episode |
| In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease. |
|
|---|
|
|
|
Learn how to improve yield and reproducibility with advanced sample prep for a variety of multiomics use cases, especially for suboptimal biospecimens. See how to get quality results from complex samples thanks to key innovations in ultrasonication. Learn more.
|
|
| Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| WhitepaperCell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| WhitepaperEconomic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
| WhitepaperFrom Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| |
|
